Skip to main content
SpringerLink
Log in

Hepatitis C and Liver Transplantation in the HIV Co-infected Patients

  • Chapter
  • First Online:
Hepatitis C Virus and Liver Transplantation

  • 981 Accesses

Abstract

The introduction of antiretroviral therapies (cART) has improved the survival of patients infected with human immunodeficiency virus (HIV). Because of shared ways of transmission, 30 % of HIV-infected patients have hepatitis B virus (HBV) or hepatitis C virus (HCV) co-infection; so, till date, liver disease is a major cause of non-acquired immunodeficiency syndrome (AIDS)-related deaths. Survival of HIV-infected patients with end-stage liver disease is shorter than in the non-HIV-infected patients. For this reason, liver transplantation (LT) must be evaluated after the first episode of liver decompensation. The risk of opportunistic disease after LT is low, while HCV recurrence is the central problem and affects post-transplant patients’ survival. Standard anti-HCV therapy with pegylated interferon and ribavirin resulted in a low response rate. This should change with the advent of new anti-HCV drugs with better antiviral activity. This would allow viral control from the time of transplant and will improve the results of LT in HCV/HIV co-infected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010 Oct;55(2):262–70.

    Article  PubMed  Google Scholar 

  2. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. EuroSIDA study group. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002;16(12):1663–71.

    Article  PubMed  CAS  Google Scholar 

  3. Weber R, Sabin CA, Friss-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver related deaths in persons infected with the human insufficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632–41.

    Article  PubMed  Google Scholar 

  4. Joshi S, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;17:65–76.

    Google Scholar 

  5. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalité 2000 and 2005” surveys (ANRS EN19 and Mortavic). J Aquir Immune Defic Syndr. 2008;48:590–8.

    Article  Google Scholar 

  6. Samuel D, Weber R, Stock P, Duclos-Vallée JC, Terrault N. Are HIV-infected patients candidates for liver transplantation. J Hepatol. 2008;48:697–707.

    Article  PubMed  Google Scholar 

  7. Duclos-Vallée JC, Feray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008:47: 407–417.

    Google Scholar 

  8. Tateo M, Roque-Afonso AM, Antonini TM, Medja F, Lombès A, Jardel C, et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS. 2009;23:1069–76.

    Article  PubMed  Google Scholar 

  9. Miro JM, Montejo M, Castells L, Rafecas A, Moreno S, Agüero F, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012 Jul;12(7):1866–76.

    Article  PubMed  CAS  Google Scholar 

  10. Terrault N, Roland M, Schiano T, Dove L, Wong M, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716–26.

    Article  PubMed  Google Scholar 

  11. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Mortality 2000 study group. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42(6):799–805.

    Article  PubMed  CAS  Google Scholar 

  12. Rockstroh JK, Splenger U. HIV and hepatitis C virus coinfection. Lancet Infect Dis. 2004;4:437–44.

    Article  PubMed  Google Scholar 

  13. European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS. 2011 Feb 20;25(4):399–409.

    Google Scholar 

  14. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1993 Jun;6(6):602–10.

    PubMed  CAS  Google Scholar 

  15. Soto B, Sánchez-Quijano A, Rodrigo L, Del Olmo JA, Garcàa-Bengoechea M, Hernández-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997 Jan;26(1):1–5.

    Article  PubMed  CAS  Google Scholar 

  16. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999 Oct;30(4):1054–8.

    Article  PubMed  CAS  Google Scholar 

  17. Martàn-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004 Jan 1;38(1):128–33.

    Article  Google Scholar 

  18. Pineda JA, Aguilar-Guisado M, Rivero A, Girón-González JA, Ruiz-Morales J, Merino D, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis. 2009 Oct 15;49(8):1274–82.

    Article  PubMed  Google Scholar 

  19. Pineda JA, Romero-Gómez M, Dàaz-Garcàa F, Girón-González JA, Montero JL, Torre-Cisneros J, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005 Apr;41(4):779–89.

    Article  PubMed  Google Scholar 

  20. Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl. 2005 Nov;11(11):1425–30.

    Article  PubMed  Google Scholar 

  21. Subramanian A, Sulkowski M, Barin B, Stablein D, Curry M, Nissen N, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology. 2010 Jan;138(1):159–64.

    Article  PubMed  Google Scholar 

  22. Stock P, Roland M, Carlson L, Freise C, Hirose R, Terrault N, et al Solid organ transplantation in HIV-positive patients. Transplant Proc. 2001 Nov-Dec; 33(7–8):3646–8.

    Google Scholar 

  23. Duclos-Vallée JC, Féray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008 Feb;47(2):407–17.

    Article  PubMed  Google Scholar 

  24. Cooper C, Kanters S, Klein M, Chaudhury P, Marotta P, Wong P, et al. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS. 2011 Mar 27;25(6):777–86.

    Article  PubMed  Google Scholar 

  25. Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation. 2003 Jul 27;76(2):370–5.

    Article  PubMed  Google Scholar 

  26. Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010 Nov 18;363(21):2004–14.

    Article  PubMed  CAS  Google Scholar 

  27. Rabie R, Mumtaz K, Renner EL. Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis. Liver Transpl. 2013 Jan;19(1):36–48.

    Article  PubMed  Google Scholar 

  28. Moreno A, Cervera C, Fortún J, Blanes M, Montejo E, Abradelo M, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl. 2012 Jan;18(1):70–81.

    Article  PubMed  Google Scholar 

  29. Teicher E, Duclos-Vallée JC. Opportunistic infections after liver transplantation in patients infected with human immunodeficiency virus. Liver Transpl. 2012 Mar;18(3):376–7.

    Article  PubMed  Google Scholar 

  30. Harbell J, Fung J, Nissen N, Olthoff K, Florman SS, Hanto DW, et al. Surgical complications in 275 HIV-infected liver and/or kidney transplantation recipients. Surgery. 2012 Sep;152(3):376–81.

    Article  PubMed  Google Scholar 

  31. Cherian PT, Alrabih W, Douiri A, Quaglia A, Heneghan MA, O’Grady J, et al. Liver transplantation in human immunodeficiency virus-infected patients: procoagulant, but is antithrombotic prophylaxis required? Liver Transpl. 2012 Jan;18(1):82–8.

    Article  PubMed  Google Scholar 

  32. Gastaca M, Valdivieso A, Montejo M, Bustamante J, de Urbina JO. Is antithrombotic prophylaxis required after liver transplantation in HIV-infected recipients? Am J Transplant. 2012 Aug;12(8):2258.

    Article  PubMed  CAS  Google Scholar 

  33. Phillips AA, Justman JE. Screening HIV-infected patients for non-AIDS defining malignancies. Curr HIV/AIDS Rep. 2009;6(2):83–92.

    Article  PubMed  Google Scholar 

  34. Vibert E, Duclos-Vallée JC, Ghigna MR, Hoti E, Salloum C, Guettier C, et al. Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. Hepatology. 2011 Feb;53(2):475–82.

    Article  PubMed  Google Scholar 

  35. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000;32:852–8.

    Article  PubMed  CAS  Google Scholar 

  36. Antonini TM, Sebagh M, Roque-Afonso AM, Teicher E, Roche B, Sobesky R, et al. Fibrosing cholestatic hepatitis in HIV/HCV coinfected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant. 2011 Aug;11(8):1686–95.

    Article  PubMed  CAS  Google Scholar 

  37. Duclos-Vallee JC, Tateo MG, Teicher E, Roque-Afonso AM, Sebagh M, Antonini TM, et al Results of liver transplantation in a large cohort of more than 100 HIV infected patients—a monocentric experience. Hepatology. 2011;54 (Suppl1):66A.

    Google Scholar 

  38. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.

    Article  PubMed  CAS  Google Scholar 

  39. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17.

    Article  PubMed  CAS  Google Scholar 

  40. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.

    Article  PubMed  CAS  Google Scholar 

  41. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.

    Article  PubMed  CAS  Google Scholar 

  42. Sulkowski M, Sherman K, Soriano V, Rockstroh J, Dieterich D, Girard PM, et al Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR24 final study results. Hepatology. 2012;56 (suppl1):219A.

    Google Scholar 

  43. Sulkowski M, Pol S, Cooper C, Fainboim H, Slim J, Rivero A, et al Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV-co-infected patients: end of treatment (week-48) interim results. In: Retroviruses and opportunistic infection, 2012 March 5–8; Washington, USA, abstract 47.

    Google Scholar 

  44. European AIDS clinical society guidelines, November 2012, Version 6.1. http://www.europeanaidsclinicalsociety.org.Accessed December, 2012.

  45. Hulskotte E, Gupta S, Xuan F, van Zutven M, O’Mara E, Feng HP, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012;56:1622–30.

    Article  PubMed  CAS  Google Scholar 

  46. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54:20–7.

    Article  PubMed  CAS  Google Scholar 

  47. Coilly A, Furlan V, Roche B, Barau C, Noël C, Bonhomme-Faivre L, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother. 2012;56:5728–34.

    Article  PubMed  CAS  Google Scholar 

  48. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, et al. Short report: telaprevir-based triple therapy in liver transplanted HCV patients: a 12 week pilot study providing safety and efficacy. Liver Transpl. 2012 Dec;18(12):1464–70.

    Article  PubMed  Google Scholar 

  49. Samuel D, Duclos-Vallee JC. Liver transplantation in the human immunodeficiency virus-hepatitis C virus coinfected patient: time to sum up. Hepatology. 2013 Jan;57(1):409–11.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, 12 Avenue Paul Vaillant Couturier, Villejuif, France

    Teresa Maria Antonini MD, Jean Charles Duclos-Vallée MD, PhD & Didier Samuel MD, PhD

  2. Université Paris-Sud, Villejuif, France

    Teresa Maria Antonini MD, Jean Charles Duclos-Vallée MD, PhD & Didier Samuel MD, PhD

  3. INSERM, Unit 785, Villejuif, France

    Teresa Maria Antonini MD, Jean Charles Duclos-Vallée MD, PhD & Didier Samuel MD, PhD

Authors
  1. Teresa Maria Antonini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean Charles Duclos-Vallée MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Didier Samuel MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Didier Samuel MD, PhD .

Editor information

Editors and Affiliations

  1. La Fe Hospital, University of Valencia and Ciberehd, Valencia, Spain

    Marina Berenguer

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Antonini, T., Duclos-Vallée, J., Samuel, D. (2014). Hepatitis C and Liver Transplantation in the HIV Co-infected Patients. In: Berenguer, M. (eds) Hepatitis C Virus and Liver Transplantation. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8438-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8438-7_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8437-0

  • Online ISBN: 978-1-4614-8438-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation